Retrophin is a biopharmaceutical company that develops and commercializes drugs for the treatment of rare diseases. The company's product portfolio includes drugs for the treatment of nephropathic cystinosis, a rare genetic disorder that affects the kidneys, and for the treatment of focal segmental glomerulosclerosis, a rare kidney disease. Retrophin also has a pipeline of drugs in development for the treatment of other rare diseases. The company was founded in 2011 and is headquartered in San Diego, California.